Page 70 - Read Online

Page 14 of 18 Orsini et al. J Transl Genet Genom 2018;2:16. I https://doi.org/10.20517/jtgg.2018.14

10. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009;50:1-23.
11. Walker LE, Mirza N, Yip VLM, Marson AG, Pirmohamed M. Personalized medicine approaches in epilepsy. J Intern Med
2015;277:218-34.
12. Lopez-Garcia MA, Feria-Romero IA, Fernando-Serrano H, Escalante-Santiago D, Grijalva I, et al. Genetic polymorphisms associated with
antiepileptic metabolism. Front Biosci (Elite Ed) 2014;6:377-86.
13. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, et al. Clinical pharmacogenetics implementation consortium guidelines for
CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther 2014;96:542-8.
14. Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, et al. A candidate gene study of antiepileptic drug tolerability and efficacy identifies
an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 2011;18:1159-64.
15. Franco V, Perucca E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opin Drug Metab
Toxicol 2015;11:1269-79.
16. Goto S, Seo T, Murata T, Nakada N, Ueda N, et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms
on phenobarbital clearance in Japanese. Ther Drug Monit 2007;29:118-21.
17. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug
monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia
2008;49:1239-76.
18. Okada Y, Seo T, Ishitsu T, Wanibuchi A, Hashimoto N, et al. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5
polymorphisms on zonisamide clearance. Ther Drug Monit 2008;30:540-3.
19. Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin
4-ene-valproic acid. J Pharmacol Exp Ther 1997;283:698-703.
20. Bűdi T, Tóth K, Nagy A, Szever Z, Kiss Á, et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia
2015;56:849-55.
21. Wang C, Wang P, Yang LP, Pan J, Yang X, et al. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with
adverse effects of valproic acid in Chinese patients with epilepsy. Epilepsy Res 2017;132:64-9.
22. Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, et al. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C > T
polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Ther Drug Monit 2014;36:406-9.
23. Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated
hyperbilirubinaemia (Gilbert’s syndrome). Br J Clin Pharmacol 1989;28:117-20.
24. Wang Q, Liang M, Dong Y, Yun W, Qiu F, et al. Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese
children with epilepsy. Drug Metab Pharmacokinet 2015;30:209-13.
25. Chang Y, Yang LY, Zhang MC, Liu SY. Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy
of lamotrigine in Han Chinese of Northern China. Eur J Clin Pharmacol 2014;70:941-6.
26. Hermann R, Borlak J, Munzel U, Niebch G, Fuhr U, et al. The role of Gilbert’s syndrome and frequent NAT2 slow acetylation
polymorphisms in the pharmacokinetics of retigabine. Pharmacogenomics J 2006;6:211-9.
27. Tompson DJ, Crean CS. Clinical Pharmacokinetics of retigabine/ezogabine. Curr Clin Pharmacol 2013;8:319-31.
28. Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. Lancet 2015;385:884-98.
29. Sisodiya SM, Marini C. Genetics of antiepileptic drug resistance. Curr Opin Neurol 2009;22:150-6.
30. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system.
Pharmacol Rev 2006;58:140-61.
31. Potschka H, Brodie MJ. Pharmacoresistance. Handb Clin Neurol 2012;108:741-57.
32. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, et al. Association of multidrug resistance in epilepsy with a polymorphism in the
drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-8.
33. Haerian BS, Lim KS, Mohamed EH, Tan HJ, Tan CT, et al. Lack of association of ABCB1 and PXR polymorphisms with response to
treatment in epilepsy. Seizure 2011;20:387-94.
34. Manna I, Gambardella A, Labate A, Mumoli L, Ferlazzo E. Polymorphism of the multidrug resistance 1 gene MDR1/ABCB1 C3435T and
response to antiepileptic drug treatment in temporal lobe epilepsy. Seizure 2015;24:124-6.
35. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, et al. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and
resistance to anticonvulsant drugs: a meta-analysis. Epilepsia 2009;50:898-903.
36. Keangpraphun T, Towanabut S, Chinvarun Y, Kijsanayotin P. Association of ABCB1 C3435T polymorphism with phenobarbital resistance
in Thai patients with epilepsy. J Clin Pharm Ther 2015;40:315-9.
37. Chouchi M, Kaabachi W, Klaa H, Tizaoui K, Turki IB, et al. Relationship between ABCB1 3435TT genotype and antiepileptic drugs
resistance in epilepsy: updated systematic review and meta-analysis. BMC Neurol 2017;17:32.
38. Kim DW, Lee SK, Chu K, Jang IJ, Yu KS, et al. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and
multidrug resistance in partial epilepsy. Epilepsy Res 2009;84:86-90.
39. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2
-24C > T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 2009;19:353-62.
40. Sun Y, Luo X, Yang K, Sun X, Li X, et al. Neural overexpression of multidrug resistance-associated protein 1 and refractory epilepsy: a
meta-analysis of nine studies. Int J Neurosci 2016;126:308-17.